Not Yet RecruitingPhase 1

Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma

18 participantsStarted 2026-05-01

Plain-language summary

This study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Creatinine ≤ 1.5 × ULN;
✓. Left ventricular ejection fraction ≥ 50%;
✓. Blood oxygen saturation \> 90%;
✓. Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN;

What they're measuring

Safety indicators

Timeframe: 6 months after CAR-T infusion

Trial details

NCT IDNCT07539688

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-03-01

Contact for this trial

Liang Huang

02223608359 huangliang@ihcams.ac.cn

View on ClinicalTrials.gov More Relapsed/Refractory B-cell Lymphoma trials